famotinib

PreclinicalSmall molecule

JJin LI

famotinib is one of 43 small molecule programs targeting Cervical Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerActive, not recruiting

Cervical CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Emend IV

Merck & Co.

Phase 3

1 2

Hycamtin

MMeitheal

Phase 3

9 3

Navelbine

PPierre Fabre Medicament

Phase 3

3 4

Gemzar

Eli Lilly

Phase 3

1 5

Rescue

Merck & Co.

Phase 3

1 6

Vindesine

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

1 7

Mitomycin C

GGynecologic Oncology Group

Phase 3

1 8

HLX10

Shanghai Henlius Biotech

Phase 3

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Phase 3

1 10

SHR-A2102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

N/ANot yet recruiting

Cervical Cancer

NCT07466901

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

Not yet recruiting·JJin LI·N/A·NCT07466901·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for famotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — famotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for famotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jin LI company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJin LI

famotinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News